208 related articles for article (PubMed ID: 25855099)
21. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
[TBL] [Abstract][Full Text] [Related]
22. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients.
Vally H; Taylor ML; Thompson PJ
Thorax; 2002 Jul; 57(7):569-74. PubMed ID: 12096197
[TBL] [Abstract][Full Text] [Related]
23. Aspirin-exacerbated respiratory disease: clinical disease and diagnosis.
Bochenek G; Niżankowska-Mogilnicka E
Immunol Allergy Clin North Am; 2013 May; 33(2):147-61. PubMed ID: 23639705
[TBL] [Abstract][Full Text] [Related]
24. The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease.
Tajudeen BA; Schwartz JS; Bosso JV
Curr Opin Otolaryngol Head Neck Surg; 2017 Feb; 25(1):30-34. PubMed ID: 27849653
[TBL] [Abstract][Full Text] [Related]
25. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs.
Doña I; Barrionuevo E; Salas M; Laguna JJ; Agúndez J; García-Martín E; Bogas G; Perkins JR; Cornejo-García JA; Torres MJ
Sci Rep; 2018 Nov; 8(1):16710. PubMed ID: 30420763
[TBL] [Abstract][Full Text] [Related]
26. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
Berges-Gimeno MP; Simon RA; Stevenson DD
Clin Exp Allergy; 2002 Oct; 32(10):1491-6. PubMed ID: 12372130
[TBL] [Abstract][Full Text] [Related]
27. Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease.
Waldram JD; Simon RA
Immunol Allergy Clin North Am; 2016 Nov; 36(4):693-703. PubMed ID: 27712764
[TBL] [Abstract][Full Text] [Related]
28. Lipid Mediators in Aspirin-Exacerbated Respiratory Disease.
Parker AR; Ayars AG; Altman MC; Henderson WR
Immunol Allergy Clin North Am; 2016 Nov; 36(4):749-763. PubMed ID: 27712768
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.
Cahill KN; Laidlaw TM
Immunol Allergy Clin North Am; 2016 Nov; 36(4):681-691. PubMed ID: 27712763
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Benefit with Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
Hill J; Burnett T; Katial R
Immunol Allergy Clin North Am; 2016 Nov; 36(4):735-747. PubMed ID: 27712767
[TBL] [Abstract][Full Text] [Related]
31. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
32. Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study.
Waldram J; Walters K; Simon R; Woessner K; Waalen J; White A
J Allergy Clin Immunol; 2018 Jan; 141(1):250-256. PubMed ID: 28550988
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for severe adult-onset asthma: a multi-factor approach.
Toppila-Salmi S; Lemmetyinen R; Chanoine S; Karjalainen J; Pekkanen J; Bousquet J; Siroux V
BMC Pulm Med; 2021 Jul; 21(1):214. PubMed ID: 34238263
[TBL] [Abstract][Full Text] [Related]
34. Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions.
Saff RR; Banerji A
Allergy Asthma Proc; 2015; 36(1):34-9. PubMed ID: 25562554
[TBL] [Abstract][Full Text] [Related]
35. Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease.
Ayuso P; Plaza-Serón Mdel C; Blanca-López N; Doña I; Campo P; Canto G; Laguna JJ; Bartra J; Soriano-Gomis V; Blanca M; Cornejo-García JA; Perkins JR
Pharmacogenomics; 2015 Jul; 16(8):825-39. PubMed ID: 26067486
[TBL] [Abstract][Full Text] [Related]
36. [Special features of NSAID intolerance in children].
Porto Arceo JA
Allergol Immunopathol (Madr); 2003; 31(3):109-25. PubMed ID: 12783761
[TBL] [Abstract][Full Text] [Related]
37. Contribution of dipeptidyl peptidase 10 to airway dysfunction in patients with NSAID-exacerbated respiratory disease.
Sim S; Choi Y; Lee DH; Lee HR; Seob Shin Y; Park HS
Clin Exp Allergy; 2022 Jan; 52(1):115-126. PubMed ID: 34431147
[TBL] [Abstract][Full Text] [Related]
38. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Fraj J; Valero A; Vives R; Pérez I; Borja J; Izquierdo I; Picado C
Allergy; 2008 Jan; 63(1):112-5. PubMed ID: 18053020
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease.
Bochenek G; Szafraniec K; Kuschill-Dziurda J; Nizankowska-Mogilnicka E
Respir Med; 2015 May; 109(5):588-95. PubMed ID: 25820158
[TBL] [Abstract][Full Text] [Related]
40. Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic.
Gawlewicz-Mroczka A; Pytlewski A; Celejewska-Wójcik N; Ćmiel A; Gielicz A; Sanak M; Mastalerz L
Clin Transl Allergy; 2022 Oct; 12(10):e12201. PubMed ID: 36267429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
